Surf Wiki
Save to docs
general/2c-psychedelics

From Surf Wiki (app.surf) — the open knowledge base

2C (psychedelics)

Family of phenethylamine psychedelics

Family of phenethylamine psychedelics

2C ('*2C-*x''''') is a general name for the family of psychedelic phenethylamines containing methoxy groups on the 2 and 5 positions of a benzene ring. Most of these compounds also carry lipophilic substituents at the 4 position, usually resulting in more potent and more metabolically stable and longer acting compounds.

Most of the early 2C drugs were developed by Alexander Shulgin in the 1970s and 1980s and were reviewed in his 1991 book PiHKAL (Phenethylamines I Have Known And Loved). 2C-B is the most popular of the 2C drugs.

Use and effects

The 2C drugs are orally active, are used at oral doses of 6 to 150mg depending on the drug, and have durations of 3 to 48hours depending on the drug. However, many have doses in the range of 10 to 60mg and durations in the range of 4 to 12hours. The 2C drugs produce psychedelic effects, such as perceptual enhancement, psychedelic visuals, and euphoria. Some, such as 2C-B, have also been reported to produce some entactogen-like effects, but findings in this area appear to be mixed.

CompoundChemical nameDoseDuration
[2C-AL](2c-al)4-Allyl-2,5-dimethoxyphenethylamineUnknownUnknown
[2C-B](2c-b)4-Bromo-2,5-dimethoxyphenethylamine10–35mg4–8 hours
[2C-Bu](2c-bu)4-Butyl-2,5-dimethoxyphenethylamineUnknownUnknown
[2C-C](2c-c)4-Chloro-2,5-dimethoxyphenethylamine20–40mg4–8 hours
[2C-CN](2c-cn)4-Cyano-2,5-dimethoxyphenethylamine22mgUnknown
[2C-CP](2c-cp)4-Cyclopropyl-2,5-dimethoxyphenethylamine15–35mg3–6 hours
[2C-D](2c-d) (2C-M)4-Methyl-2,5-dimethoxyphenethylamine20–60mg4–6 hours
[2C-E](2c-e)4-Ethyl-2,5-dimethoxyphenethylamine10–25mg6–12 hours
[2C-EF](2c-ef)4-Fluoroethyl-2,5-dimethoxyphenethylamine10–25mgUnknown
[2C-F](2c-f)4-Fluoro-2,5-dimethoxyphenethylamine≥250mgUnknown
[2C-G](2c-g) (2C-G-0)3,4-Dimethyl-2,5-dimethoxyphenethylamine20–35mg18–30 hours
[2C-G-3](2c-g-3)3,4-Trimethylene-2,5-dimethoxyphenethylamine16–25mg12–24 hours
[2C-G-5](2c-g-5)3,4-Norbornyl-2,5-dimethoxyphenethylamine10–16mg32–48 hours
[2C-G-N](2c-g-n)1,4-Dimethoxynaphthyl-2-ethylamine20–40 mg20–30 hours
[2C-H](2c-h) (2,5-DMPEA)2,5-DimethoxyphenethylamineUnknownUnknown
[2C-I](2c-i)4-Iodo-2,5-dimethoxyphenethylamine14–22mg6–10 hours
[2C-iBu](2c-ibu)4-Isobutyl-2,5-dimethoxyphenethylamine≥5mg~20 hours
[2C-iP](2c-ip)4-Isopropyl-2,5-dimethoxyphenethylamine8–25mg8–12 hours
[2C-N](2c-n)4-Nitro-2,5-dimethoxyphenethylamine100–150mg4–6 hours
[2C-O](2c-o) (2,4,5-TMPEA)4-Methoxy-2,5-dimethoxyphenethylamine300mgUnknown
[2C-O-4](2c-o-4)4-Isopropoxy-2,5-dimethoxyphenethylamine60mgUnknown
[2C-O-22](2c-o-22)4-(2,2,2-Trifluoroethoxy)-2,5-dimethoxyphenethylamine≥57mgUnknown
[2C-P](2c-p)4-Propyl-2,5-dimethoxyphenethylamine6–10mg5–16 hours
[2C-Ph](2c-ph) (2C-BI-1)4-Phenyl-2,5-dimethoxyphenethylamineUnknownUnknown
[2C-Se](2c-se)4-Methylseleno-2,5-dimethoxyphenethylamine~100mg6–8 hours
[2C-T](2c-t) (2C-T-1)4-Methylthio-2,5-dimethoxyphenethylamine60–100mg3–5 hours
[2C-T-2](2c-t-2)4-Ethylthio-2,5-dimethoxyphenethylamine12–25mg6–8 hours
[2C-T-3](2c-t-3) (2C-T-20)4-Methallylthio-2,5-dimethoxyphenethylamine15–40mg8–14 hours
[2C-T-4](2c-t-4)4-Isopropylthio-2,5-dimethoxyphenethylamine8–20mg12–18 hours
[2C-T-7](2c-t-7)4-Propylthio-2,5-dimethoxyphenethylamine10–30mg8–15 hours
[2C-T-8](2c-t-8)4-Cyclopropylmethylthio-2,5-dimethoxyphenethylamine30–50mg10–15 hours
[2C-T-9](2c-t-9)4-*tert*-Butylthio-2,5-dimethoxyphenethylamine60–100mg12–18 hours
[2C-T-13](2c-t-13)4-(2-Methoxyethylthio)-2,5-dimethoxyphenethylamine25–40mg6–8 hours
[2C-T-15](2c-t-15)4-Cyclopropylthio-2,5-dimethoxyphenethylamine30mgSeveral hours
[2C-T-16](2c-t-16)4-Allylthio-2,5-dimethoxyphenethylamine10–25mg4–6 hours
[2C-T-17](2c-t-17)4-*sec*-Butylthio-2,5-dimethoxyphenethylamine60–100mg10–15 hours
[2C-T-19](2c-t-19)4-Butylthio-2,5-dimethoxyphenethylamineUnknownUnknown
[2C-T-21](2c-t-21)4-(2-Fluoroethylthio)-2,5-dimethoxyphenethylamine8–20mg7–10 hours
[2C-T-21.5](2c-t-21-5)4-(2,2-Difluoroethylthio)-2,5-dimethoxyphenethylamine12–30mg8–14 hours
[2C-T-22](2c-t-22)4-(2,2,2-Trifluoroethylthio)-2,5-dimethoxyphenethylamine10mg~6 hours
[2C-T-25](2c-t-25)4-Isobutylthio-2,5-dimethoxyphenethylamine30mgUnknown
[2C-T-27](2c-t-27)4-Benzylthio-2,5-dimethoxyphenethylamine≥80mgUnknown
[2C-T-28](2c-t-28)4-(3-Fluoropropylthio)-2,5-dimethoxyphenethylamine8–20mg8–10 hours
[2C-T-30](2c-t-30)4-(4-Fluorobutylthio)-2,5-dimethoxyphenethylamine8mgUnknown
[2C-T-33](2c-t-33)4-(3-Methoxybenzylthio)-2,5-dimethoxyphenethylamineUnknownUnknown
[2C-T-36](2c-t-36) (2C-T-TFM)4-Trifluoromethylthio-2,5-dimethoxyphenethylamineUnknownUnknown
[2C-tBu](2c-tbu)4-*tert*-Butyl-2,5-dimethoxyphenethylamine5–10mgUnknown
[2C-Te](2c-te)4-Methyltelluro-2,5-dimethoxyphenethylamineUnknownUnknown
[2C-TFE](2c-tfe)4-(2,2,2-Trifluoroethyl)-2,5-dimethoxyphenethylamine5–15mg12–24 hours
[2C-TFM](2c-tfm)4-Trifluoromethyl-2,5-dimethoxyphenethylamine3–6mg≥5–10 hours
[2C-V](2c-v)4-Ethenyl-2,5-dimethoxyphenethylamine~25mg~5 hours
[2C-YN](2c-yn)4-Ethynyl-2,5-dimethoxyphenethylamine~50mg~2 hours
**Refs:**

Interactions

The 2C drugs are metabolized by the monoamine oxidase (MAO) enzymes, including both MAO-A and MAO-B. As a result, they may be potentiated by monoamine oxidase inhibitors (MAOIs), such as phenelzine, tranylcypromine, moclobemide, and selegiline. This may lead to overdose and serious toxicity. There are anecdotal reports of strong potentiation of 2C-B by MAOIs, including hospitalization. There is no known reversal agent for 2C drugs, and medical management for overdose involves treatment of symptoms until toxicity within the body subsides.

Pharmacology

Pharmacodynamics

Actions

The 2C drugs act as agonists of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. They are partial agonists of the serotonin 5-HT2A receptor. Most of the 2C drugs have much lower affinity for the serotonin 5-HT1A receptor than for the serotonin 5-HT2A receptor. Most of the 2C drugs have also shown about 5- to 15-fold higher affinity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor and about 15- to 100-fold higher affinity for the serotonin 5-HT2A receptor over the serotonin 5-HT1A receptor. The psychedelic effects of the 2C drugs are thought to be mediated specifically by activation of the serotonin 5-HT2A receptor.

Unlike many other phenethylamines, 2C drugs, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2 among others, are inactive as monoamine releasing agents and reuptake inhibitors. Most of the 2C drugs are agonists of the rat and mouse trace amine-associated receptor 1 (TAAR1). However, most are inactive as agonists of the human TAAR1. The 2C drugs show very weak monoamine oxidase inhibition, including of monoamine oxidase A (MAO-A) and/or monoamine oxidase B (MAO-B).

Drug[5-HT1A](5-ht1a-receptor)[5-HT1B](5-ht1b-receptor)[5-HT2A](5-ht2a-receptor)[5-HT2B](5-ht2b-receptor)[5-HT2C](5-ht2c-receptor)Ki (nM)EC50 (nM)Emax (%)Ki (nM)Ki (nM)EC50 (nM)Emax (%)Ki (nM)EC50 (nM)Emax (%)Ki (nM)EC50 (nM)Emax (%)
[2C-B](2-5-dimethoxy-4-bromophenethylamine)130–311NDND104.46.9–27.61.89–80
[2C-C](2-5-dimethoxy-4-chlorophenethylamine)190–74010,000252.95.47–139.27–200
[2C-D](2-5-dimethoxy-4-methylphenethylamine)440–1,63010,000ND23.9–32.443.5–350
[2C-E](2-5-dimethoxy-4-ethylphenethylamine)307.3–1,19010,000ND4.50–43.92.5–110
[2C-H](2-5-dimethoxyphenethylamine)70NDNDND1,6002,408–9,400
[2C-I](2-5-dimethoxy-4-iodophenethylamine)180–9704,900102%ND3.5–9.33.83–60
[2C-N](2-5-dimethoxy-4-nitrophenethylamine)2,200NDNDND23.5170
[2C-P](2-5-dimethoxy-4-propylphenethylamine)110NDNDND8.190
[2C-T-1](2-5-dimethoxy-4-methylthiophenethylamine)1,035NDNDND492.0
[2C-T-2](2-5-dimethoxy-4-ethylthiophenethylamine)370–1,7403,00076%857.59–39.90.354–80
[2C-T-4](2-5-dimethoxy-4-isopropylthiophenethylamine)470–916NDNDND27.9–545.5–220
[2C-T-7](2-5-dimethoxy-4-propylthiophenethylamine)520–878NDNDND5.3–6.51.2–130
**Notes:** The smaller the value, the more avidly the drug binds to or activates the site. **Refs:**

Effects

In accordance with their psychedelic effects in humans, the 2C drugs produce the head-twitch response and wet dog shakes, behavioral proxies of psychedelic effects, in rodents. At least some 2C drugs, such as 2C-D and 2C-E, produce hyperlocomotion at lower doses in rodents. All 2C drugs produce hypolocomotion at higher doses in rodents. 2C drugs, including 2C-C, 2C-D, 2C-E, and 2C-I, substitute partially to fully for psychedelics like DOM, DMT, and LSD and/or for the entactogen MDMA in rodent drug discrimination tests. However, none of the assessed 2C drugs substituted for dextromethamphetamine, suggesting that they lack amphetamine-type or stimulant-like effects.

In contrast to most psychedelics, at least two assessed 2C drugs, 2C-C and 2C-P, have shown reinforcing effects in rodents, including conditioned place preference (CPP) and self-administration. The mechanism by which these effects are mediated is unknown. However, it may be related to reduced expression of the dopamine transporter (DAT) and increased DAT phosphorylation, in turn resulting in increased extracellular dopamine levels in certain brain areas. These 2C drugs might have misuse potential in humans. Similar reinforcing effects in animals have been observed for NBOMe analogues of 2C drugs, including 25B-NBOMe, 25D-NBOMe, 25E-NBOMe, 25H-NBOMe, and 25N-NBOMe.

Similarly to DOI, tolerance has been found to gradually develop to the head-twitch response induced by 2C-T-7 with chronic administration in rodents.

Various 2C drugs show potent anti-inflammatory effects mediated by serotonin 5-HT2A receptor activation. Among these include 2C-I, 2C-B, 2C-H, and 2C-iBu. Others, such as 2C-B-Fly and 2C-T-33, were less effective. 2C-iBu has shown a greater separation between anti-inflammatory effects and psychedelic-like effects in animals than other 2C drugs and is being investigated for possible use as a pharmaceutical drug.

Pharmacokinetics

The 2C drugs are orally active. They are metabolized by O-demethylation and deamination. This is mediated specifically by monoamine oxidase (MAO) enzymes MAO-A and MAO-B, whereas cytochrome P450 enzymes appear to metabolize only some 2C drugs and to have only a very small role.

Chemistry

The 2C drugs, also known as 4-substituted 2,5-dimethoxyphenethylamines, are substituted phenethylamines and can be thought of as synthetic analogues of the naturally occurring phenethylamine psychedelic mescaline (3,4,5-trimethoxyphenethylamine). They are the phenethylamine (2C) analogues of the amphetamine (α-methylphenethylamine) DOx drugs like DOM, DOB, and DOI as well as of the phenylisobutylamine (α-ethylphenethylamine) 4C drugs like Ariadne (4C-D) and 4C-B. The N-benzylphenethylamines such as 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe are derivatives of the 2C drugs. Certain FLY drugs such as 2C-B-FLY are also 2C derivatives.

Syntheses

The chemical syntheses of 2C drugs have been described.

Analysis

The chemical analysis of 2C drugs has been described.

History

2,4,5-Trimethoxyphenethylamine (2,4,5-TMPEA; 2C-O), the 2C positional isomer of mescaline (3,4,5-trimethoxyphenethylamine), was first synthesized by Max Jansen and was reported to produce psychedelic effects similar to those of mescaline in 1931. However, subsequent studies in the 1960s and 1970s suggested that 2,4,5-TMPEA may actually be inactive as a psychedelic in animals and humans.

2C-D was the first of the 2C drugs after 2C-O to be discovered. It was synthesized and studied in animals by Beng T. Ho and colleagues at the Texas Research Institute of Mental Sciences and they published their findings in 1970. Alexander Shulgin synthesized 2C-B and 2C-D in 1974 and discovered their psychedelic effects in self-experiments conducted in 1974 and 1975. He published his findings in the scientific literature in 1975. However, Shulgin had previously tested sub-threshold doses of 2C-D in 1964 and 1965. 2C-T was first described by Shulgin and David E. Nichols in 1976. 2C-I was first described by Shulgin and colleagues in 1977 and initial psychoactivity was reported by Shulgin in 1978. Shulgin also first synthesized 2C-E in 1977. He reviewed several of these 2C drugs in a literature review in 1979. Subsequently, numerous other 2C drugs have been synthesized and characterized. Shulgin comprehensively reviewed and described the 2C drugs in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). He coined the term "2C", this term being an acronym for the two carbon atoms between the benzene ring and the amino group of the 2C drugs and a means to distinguish them from the three-carbon DOx drugs.

2C-D was extensively studied by Hanscarl Leuner under the names DMM-PEA and LE-25 in psychedelic-assisted psychotherapy in Germany in the 1970s and 1980s. It was also informally studied by Darrell Lemaire as a potential "smart drug" in the 1970s and 1980s. He additionally developed the TWEETIO drugs such as 2CD-5-ETO via structural modification of the 2Cs. 2C-B was legitimately marketed and sold as an over-the-counter sexual enhancer under brand names like Erox in several European countries such as Germany in the 1980s and early 1990s. It was sold in adult stores, smart shops, and some nightclubs.

2C-B was first encountered as a novel designer drug in the United States in 1979. It gained popularity as a recreational drug and MDMA (ecstasy) alternative in the mid-1980s. The drug became a controlled substance in the United States in 1994 or 1995. It has been said to be the most popular of the 2C drugs in terms of recreational use. Numerous other 2C drugs besides 2C-B have also since been made controlled substances.

Society and culture

Canada

As of October 12, 2016, the 2C-x family of substituted phenethylamines are controlled substances (Schedule III) in Canada.

List of 2C drugs

NameR3R4StructureCAS #
[2C-B](2c-b)HBr[[File:2C-B.svg115pxclass=skin-invert-image]]66142–81–2
2C-BnHCH2C6H5[[File:2C-Bn.svg115pxclass=skin-invert-image]]
[2C-Bu](2c-bu)HCH2CH2CH2CH3[[File:2C-Bu.svg115pxclass=skin-invert-image]]
[2C-C](2c-c)HCl[[File:2C-C.svg115pxclass=skin-invert-image]]88441–14–9
2C-C-3ClCl[[File:2CC3 structure.png115pxclass=skin-invert-image]]
[2C-CN](2c-cn)HC≡N[[File:2C-CN.svg115pxclass=skin-invert-image]]88441–07–0
[2C-D](2c-d)HCH3[[File:2C-D 2DACS.svg115pxclass=skin-invert-image]]24333–19–5
[2C-E](2c-e)HCH2CH3[[File:2C-E-Chemdraw.png115pxclass=skin-invert-image]]71539–34–9
[2C-EF](2c-ef)HCH2CH2F[[File:2C-EF.svg115pxclass=skin-invert-image]]1222814–77–8
[2C-F](2c-f)HF[[File:2C-F-Chemdraw.png115pxclass=skin-invert-image]]207740–15–6
[2C-G](2c-g) (2C-G-0)CH3CH3[[File:2C-G-Chemdraw.png115pxclass=skin-invert-image]]207740–18–9
[2C-G-1](2c-g-1)CH2[[File:2C-G-1.png80pxclass=skin-invert-image]]2888537-47-9
[2C-G-2](2c-g-2)(CH2)2[[File:2C-G-2.png80pxclass=skin-invert-image]]2888537-48-0
[2C-G-3](2c-g-3)(CH2)3[[File:2C-G-3-Chemdraw.png115pxclass=skin-invert-image]]207740–19–0
[2C-G-4](2c-g-4)(CH2)4[[File:2C-G-4-Chemdraw.png115pxclass=skin-invert-image]]952006–59–6
[2C-G-5](2c-g-5)(CH2)5[[File:2C-G-5.svg80pxclass=skin-invert-image]]207740–20–3
[2C-G-6](2c-g-6)(CH2)6[[File:2C-G-6.png80pxclass=skin-invert-image]]2888537-49-1
[2C-G-N](2c-g-n)(CH)4[[File:2C-G-N-Chemdraw.png115pxclass=skin-invert-image]]207740–21–4
[2C-H](2c-h)HH[[File:2C-H-Chemdraw.png115pxclass=skin-invert-image]]3600–86–0
[2C-I](2c-i)HI[[File:2C-I-Chemdraw.png115pxclass=skin-invert-image]]69587–11–7
[2C-iBu](2c-ibu)HiBu[[File:2C-iBu.svg115pxclass=skin-invert-image]]
[2C-iP](2c-ip)HCH(CH3)2[[File:2C-IP_structure.png115pxclass=skin-invert-image]]1498978–47–4
[2C-tBu](2c-tbu)HC(CH3)3[[File:2C-TBU_structure.png115pxclass=skin-invert-image]]
[2C-CP](2c-cp)HC3H5[[File:2C-cP.svg115pxclass=skin-invert-image]]2888537–46–8
2C-CBHC4H7[[File:2C-CB_structure.png115pxclass=skin-invert-image]]
[2C-CPE](2c-cpe)HC5H9[[File:2C-CPE_structure.png115pxclass=skin-invert-image]]
2C-CPMHC4H7[[File:2C-CPM_structure.png115pxclass=skin-invert-image]]
[2C-N](2c-n)HNO2[[File:2C-N-Chemdraw.png115pxclass=skin-invert-image]]261789–00–8
2C-NH2HNH2[[File:2C-NH2 structure.png115pxclass=skin-invert-image]]168699–66–9
2C-PYRHPyrrolidine[[File:2C-PYR structure.png115pxclass=skin-invert-image]]
2C-PIPHPiperidine[[File:2C-PIP structure.png115pxclass=skin-invert-image]]
[2C-O](2c-o)HOCH3[[File:2C-O.svg115pxclass=skin-invert-image]]15394–83–9
[2C-O-4](2c-o-4)HOCH(CH3)2[[File:2C-O-4-Chemdraw.png115pxclass=skin-invert-image]]952006–65–4
[2C-O-22](2c-o-22)HOCH2CF3[[File:2C-O-22 chemical structure.svg115pxclass=skin-invert-image]]
2C-MOMHCH2OCH3[[File:2C-MOM structure.png115pxclass=skin-invert-image]]
[2C-P](2c-p)HCH2CH2CH3[[File:2C-P2DACS.svg115pxclass=skin-invert-image]]207740–22–5
[2C-Ph](2c-ph) (2C-BI-1)HC6H5[[File:2C-Ph.svg115pxclass=skin-invert-image]]
[2C-Se](2c-se)HSeCH3[[File:2C-SE-Chemdraw.png115pxclass=skin-invert-image]]1189246–68–1
[2C-Se-TFM](2c-se-tfm)HSeCF3[[File:2C-Se-TFM_structure.png115pxclass=skin-invert-image]]
[2C-Te](2c-te)HTeCH3[[File:2C-Te chemical structure.svg115pxclass=skin-invert-image]]?
[2C-T](2c-t)HSCH3[[File:2C-T chemical structure.svg115pxclass=skin-invert-image]]61638–09–3
[2C-T-2](2c-t-2)HSCH2CH3[[File:2C-T-2-Chemdraw.png115pxclass=skin-invert-image]]207740–24–7
title=Shulgin's Sulfur Symphony – Part Iurl=http://countyourculture.com/2011/01/15/shulgins-sulfur-symphony-part-i/website=countyourculturedate=15 January 2011access-date=22 October 2017archive-url=https://web.archive.org/web/20190919063901/http://countyourculture.com/2011/01/15/shulgins-sulfur-symphony-part-i/archive-date=19 September 2019url-status=dead}}HSCH2C(=CH2)CH3[[File:2C-T-3.svg115pxclass=skin-invert-image]]648957–40–8
[2C-T-4](2c-t-4)HSCH(CH3)2[[File:2C-T-4-Chemdraw.png115pxclass=skin-invert-image]]207740–25–8
2C-T-5H[[File:2CT5 structure.png115pxclass=skin-invert-image]]
2C-T-6HSC6H5[[File:2CT6 structure.png115pxclass=skin-invert-image]]
[2C-T-7](2c-t-7)HS(CH2)2CH3[[File:2C-T-7-Chemdraw.png115pxclass=skin-invert-image]]207740–26–9
[2C-T-8](2c-t-8)HSCH2CH(CH2)2[[File:2C-T-8-Chemdraw.png115pxclass=skin-invert-image]]207740–27–0
[2C-T-9](2c-t-9)HSC(CH3)3[[File:2C-T-9 v2.svg115pxclass=skin-invert-image]]207740–28–1
2C-T-10H[[File:2CT10 structure.png115pxclass=skin-invert-image]]
2C-T-11HSC6H4-*p*-Br[[File:2CT11 structure.png115pxclass=skin-invert-image]]
2C-T-12H[[File:2CT12 structure.png115pxclass=skin-invert-image]]
[2C-T-13](2c-t-13)HS(CH2)2OCH3[[File:2C-T-13.svg115pxclass=skin-invert-image]]207740–30–5
2C-T-14HS(CH2)2SCH3[[File:2CT14 structure.png115pxclass=skin-invert-image]]
[2C-T-15](2c-t-15)HSCH(CH2)2[[File:2C-T-15-Chemdraw.png115pxclass=skin-invert-image]]
[2C-T-16](2c-t-16)HSCH2CH=CH2[[File:2CT16.svg120pxclass=skin-invert-image]]648957–42–0
[2C-T-17](2c-t-17)HSCH(CH3)CH2CH3[[File:2C-T-17-Chemdraw.png115pxclass=skin-invert-image]]207740–32–7
2C-T-18H[[File:2CT18 structure.png115pxclass=skin-invert-image]]
[2C-T-19](2c-t-19)HSCH2CH2CH2CH3[[File:2C-T-192DACS.svg115pxclass=skin-invert-image]]
[2C-T-21](2c-t-21)HS(CH2)2F[[File:2C-T-21-Chemdraw.png115pxclass=skin-invert-image]]207740–33–8
[2C-T-21.5](2c-t-21-5)HS(CH2)CHF2[[File:2CT21.5.svg115pxclass=skin-invert-image]]648957–46–4
[2C-T-22](2c-t-22)HS(CH2)CF3[[File:2CT22 structure.png115pxclass=skin-invert-image]]648957–48–6
2C-T-23H[[File:2CT23 structure.png115pxclass=skin-invert-image]]
2C-T-24H[[File:2CT24 structure.png115pxclass=skin-invert-image]]
[2C-T-25](2c-t-25)HSCH2CH(CH3)2[[File:2CT25 structure.png115pxclass=skin-invert-image]]
[2C-T-27](2c-t-27)HSCH2C6H5[[File:2CT27 structure.png115pxclass=skin-invert-image]]648957–52–2
[2C-T-28](2c-t-28)HS(CH2)3F[[File:2C-T-28.svg115pxclass=skin-invert-image]]648957–54–4
[2C-T-29](2c-t-29) (2C-T-PARGY)HS(CH2)C≡CH[[File:2C-T-29_structure.png115pxclass=skin-invert-image]]
[2C-T-30](2c-t-30)HS(CH2)4F[[File:2CT30 structure.png115pxclass=skin-invert-image]]
2C-T-31HSCH2C6H4-*p*-CF3[[File:2CT31 structure.png115pxclass=skin-invert-image]]
2C-T-32HSCH2C6F5[[File:2CT32 structure.png115pxclass=skin-invert-image]]
[2C-T-33](2c-t-33)HSCH2C6H4-*m*-OCH3[[File:2CT33 structure.png115pxclass=skin-invert-image]]
2C-T-34 (2C-T-FM)HSCFH2[[File:2C-T-34 structure.svg115pxclass=skin-invert-image]]
[2C-T-35](2c-t-35) (2C-T-DFM)HSCF2H[[File:2C-T-DFM_structure.png115pxclass=skin-invert-image]]
CYB210010 (2C-T-36 / 2C-T-TFM)HSCF3[[File:CYB210010_structure.png115pxclass=skin-invert-image]]
2C-T-CH2CNHS(CH2)C≡N[[File:2C-T-CH2CN_structure.png115pxclass=skin-invert-image]]
2C-T-pent-4-ynylHS(CH2)3C≡CH[[File:2C-T-CH2CH2CH2C≡CH structure.png115pxclass=skin-invert-image]]
2C-T-TFM-sulfoneHSO2CF3[[File:2C-T-TFM-sulfone_structure.png115pxclass=skin-invert-image]]
2C-T-DFPHSCH2CH2CF2H[[File:2C-T-DFP_structure.png115pxclass=skin-invert-image]]
2C-T-TFPHSCH2CH2CF3[[File:2C-T-TFP_structure.png115pxclass=skin-invert-image]]
770}}HCHF2[[File:2C-DFM.svg115pxclass=skin-invert-image]]
[2C-TFM](2c-tfm)HCF3[[File:2C-TFM-Chemdraw.png115pxclass=skin-invert-image]]159277–08–4
[2C-TFE](2c-tfe)HCH2CF3[[File:2C-TFE.svg115pxclass=skin-invert-image]]
2C-PFEHCF2CF3[[File:2C-PFE structure.png115pxclass=skin-invert-image]]
2C-PFSHSF5[[File:2C-PFS structure.png115pxclass=skin-invert-image]]
[2C-YN](2c-yn)HC≡CH[[File:2C-YN skeletal.svg115pxclass=skin-invert-image]]752982–24–4
[2C-V](2c-v)HCH=CH2[[File:2C-V.svg115pxclass=skin-invert-image]]
[2C-AL](2c-al)HCH2CH=CH2[[File:2C-AL.svg115pxclass=skin-invert-image]]
2C-1MVH1-Methylvinyl[[File:2C-1MV chemical structure.svg115pxclass=skin-invert-image]]
2C-MALHMethallyl[[File:2C-MAL chemical structure.svg115pxclass=skin-invert-image]]

References

References

  1. (March 2022). "Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences". Sci Adv.
  2. (April 2020). "Designer drugs: mechanism of action and adverse effects". Arch Toxicol.
  3. (2015). "Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions". Biomed Res Int.
  4. (August 2023). "Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition". Clin Pharmacol Ther.
  5. (October 2018). "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol.
  6. (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology.
  7. (2012). "Fluorine in psychedelic phenethylamines". Drug Test Anal.
  8. (2013). "Phenethylamine: von der Struktur zur Funktion". Nachtschatten-Verlag.
  9. (January 2024). "Drug-drug interactions involving classic psychedelics: A systematic review". J Psychopharmacol.
  10. (January 2026). "Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data". CNS Drugs.
  11. (June 2025). "Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?". Toxicol Rep.
  12. (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology.
  13. Ray, Thomas S.. (February 2010). "Psychedelics and the human receptorome". PLOS ONE.
  14. (2019). "New psychoactive substances—Synthetic stimulants". WIREs Forensic Science.
  15. (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology.
  16. (March 2014). "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function". Psychopharmacology (Berl).
  17. (July 2018). "Trace Amines and Their Receptors". Pharmacol Rev.
  18. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther.
  19. (2022). "Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α‑Desmethyl (2C) Analogues". The FASEB Journal.
  20. (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Arch Toxicol.
  21. (May 2018). "Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)". Neuropharmacology.
  22. (January 2023). "Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines". Psychopharmacology (Berl).
  23. (April 2021). "New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents". Arch Toxicol.
  24. (2020). "NBOMes-Highly Potent and Toxic Alternatives of LSD". Front Neurosci.
  25. (November 2020). "25B-NBOMe, a novel ''N''-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential". Addiction Biology.
  26. (October 2019). "A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents". Brain Res Bull.
  27. (November 2022). "Rewarding and Reinforcing Effects of 25H-NBOMe in Rodents". Brain Sci.
  28. (August 2023). "Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System". ACS Chem Neurosci.
  29. (April 2024). "The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents". Arch Pharm Res.
  30. (April 2021). "Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore". ACS Pharmacol Transl Sci.
  31. "Compounds and methods for treating inflammatory disorders".
  32. (8 July 2020). "Eleusis Draws on Research Into Psychedelics To Develop New Medicines for Inflammation".
  33. (January 2007). "Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series)". Biochem Pharmacol.
  34. (31 January 2018). "Chromatographic Techniques in the Forensic Analysis of Designer Drugs". CRC Press.
  35. Shulgin, Alexander T.. (1978). "Stimulants". Springer US.
  36. Jansen, Max. P. J. M.. (1931). "β-2: 4: 5-Trimethoxyphenylethylamine, an isomer of mescaline". Recueil des Travaux Chimiques des Pays-Bas.
  37. (2011). "The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds". Transform Press.
  38. (December 1976). "Phenylakylamines with potential psychotherapeutic utility. 1. 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)butane". J Med Chem.
  39. (January 1970). "Amphetamine analogs. II. Methylated phenethylamines". J Med Chem.
  40. (December 1970). "Effects of mescaline and 2,5-dimethoxy-4-methylphenethylamine on sleeping time in mice". J Pharm Pharmacol.
  41. (June 2013). "2C or not 2C: phenethylamine designer drug review". J Med Toxicol.
  42. (December 2020). "DARK Classics in Chemical Neuroscience: NBOMes". ACS Chem Neurosci.
  43. (1975). "Centrally active phenethylamines". Psychopharmacol Commun.
  44. "Acute Trials".
  45. "Subacute evaluation".
  46. (October 1976). "Sulfur Analogs of Psychotomimetic Amines". J Pharm Sci.
  47. (December 1977). "Synthesis and body distribution of several iodine-131 labeled centrally acting drugs". J Med Chem.
  48. (12 November 2021). "2C-x and DOx hallucinogens: A systematic review". Annals of the "Dunarea de Jos" University of Galati Fascicle II Mathematics Physics Theoretical Mechanics.
  49. Alexander Shulgin. (1980). "Pharmacology Notes II (The Shulgin Lab Books)". Erowid.
  50. (1979). "Chemistry of phenethylamines related to mescaline". J Psychedelic Drugs.
  51. (1994). "Structure-activity relationships of the classic hallucinogens and their analogs". NIDA Res Monogr.
  52. {{CitePiHKAL
  53. Passie, Torsten. (2024). "A history of the European Medical Society for Psycholytic Therapy (EPT) 1964–1974". Drug Science, Policy and Law.
  54. Passie, Torsten. (7 November 2022). "Handbook of Medical Hallucinogens". Guilford Publications.
  55. Leuner, Hanscarl. (1981). "Halluzinogene: psychische Grenzzustände in Forschung und Psychotherapie". Huber.
  56. Michael Schlichting. "Psychotrope Eigenschaften des Phenäthylamins DMM-PEA (2,5-dimethoxy-4-methyl-phenathylamin)". Göttingen University.
  57. "Erowid Darrell Lemaire Vault".
  58. (7 December 2016). "The Lazy Lizard School of Hedonism". [[Vice Media]].
  59. Hosteen Nez ([[Darrell Lemaire]]). (2010). "Radiant Minds: Scientists Explore the Dimensions of Consciousness". Millay.
  60. (1990). "Certain Exotic Transmitters as Smart Pills or Compounds that Increase the Capacity for Mental Work in Humans: A Story About LAZAR as Told by Hosteen Nez".
  61. (2003). "Hallucinogens: A Forensic Drug Handbook". Elsevier Science.
  62. (July 2012). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects". J Psychopharmacol.
  63. Johnson, Cody. (5 June 2018). "Magic Medicine: A Trip Through the Intoxicating History and Modern-Day Use of Psychedelic Plants and Substances". Fair Winds Press.
  64. (1 January 2006). "Information Bulletin 2C-B (Nexus) Reappears on the Club Drug Scene".
  65. (9 March 2012). "Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants". Wiley.
  66. (April 15, 2016). "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". [[Canada Gazette]].
  67. "Controlled Drugs and Substances Act".
  68. (2009). "Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry". Talanta.
  69. (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". Journal of Medicinal Chemistry.
  70. "Phenethylamine compounds, compositions, and methods of use.".
  71. (2016). "5-HT2A/5-HT2C receptor pharmacology and intrinsic clearance of N-benzylphenethylamines modified at the primary site of metabolism". ACS Chem. Neurosci..
  72. Daniel Trachsel. (2003). "Synthesis of novel (phenylalkyl)amines for the investigation of structure-activity relationships. Part 2. 4-Thio-substituted [2-(2,5-dimethoxyphenyl)ethyl]amines (=2,5-dimethoxybenzeneethanamines)". [[Helvetica Chimica Acta]].
  73. (Apr 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". J Med Chem.
  74. Patentscope. [https://patentscope.wipo.int/search/docs2/pct/WO2022006186/pdf/Z6QRYQjRUoLeRiOeDWcMFqiVKf3MMTkWXfeRv-Yhpxk Kruegel AC. Phenalkylamines and Methods of Treating Mood Disorders. Patent WO 2022/006186]. Retrieved 2025-05-12
  75. (January 2016). "Metabolic Fate of Hallucinogenic NBOMes". Chem Res Toxicol.
  76. (July 2024). "N-(4-Bromo-2,5-Dimethoxyphenethyl)-6-(4-Phenylbutoxy)Hexan-1-Amine (XOB): A Novel Phenylalkylamine Antagonist of Serotonin 2A Receptors and Voltage-Gated Sodium Channels". Mol Pharmacol.
  77. (May 1973). "Potential Psychotomimetics: Bromomethoxyamphetamines and Structural Congeners of Lysergic Acid". [[University of Iowa]].
  78. (1 April 2025). "2C-B-morpholine".
  79. (November 2004). "Beta-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane". J Med Chem.
  80. (May 1983). "Sulfur analogues of psychotomimetic agents. 2. Analogues of (2,5-dimethoxy-4-methylphenyl)-and (2,5-dimethoxy-4-ethylphenyl)isopropylamine". J Med Chem.
  81. "5-HT2A Agonists for Use in Treatment of Depression.".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

2c-(psychedelics) alexander-shulgin chemical-classes-of-psychoactive-drugs
Want to explore this topic further?

Ask Mako anything about 2C (psychedelics) — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report